The British Association for the Study of the Liver is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
The British Association for the Study of the Liver aims to disseminate research findings and clinical expertise, to promote opportunities for collaboration in liver research, to provide a voice that can advise and interact with the media and advises policymakers.
Dr Luke Boulter (centre) winner of the BASL Dame Sheila Sherlock Prize Lecture in 2015, he is pictured here with his team David Wilson (left) and Ronan Mellin (right). The Prize Lecture took place this year at the Basic Science Retreat where Dr Boulter was presented with a crystal award and £1,000.
Dr Tom Bird winner of the BASL Andy Burroughs Young Investigator Award 2015. This is a new award given in honour of the late Professor Andrew Burroughs. Dr Bird presented a 30 minute lecture at the BLTG Meeting and was awarded a crystal award and £1,000.
The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. Join us in Manchester from 7 - 9 September. Participating at our conference provides a unique opportunity to be part of this exciting and vibrant event.
Find out more
Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.
BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
Manchester Central, 6-9 September
|Submit and Abstract|
FIND OUT ALL OF THE INFORMATION BY VISITING OUR ANNUAL MEETING WEBSITE - CLICK HERE.
BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.
Members of BASL receive the following benefits:
- discounted registration rates for the annual meeting and other relevant meetings
- eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
- eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.
Click here to find out more about joining us.
A tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) was effective in HIV/HBV co-infected adults, a new study showed.
In this US multi-centre, open-label, non-comparative switch study, at week 48, 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA <50 c/mL; HBV DNA <29 IU/mL.)
Seroconversion occurred in 2.9% of HBsAg positive participants and 3.3% of HBeAg positive participants; 40% of those with abnormal ALT normalized. E/C/F/TAF was associated with improved renal function and reduced bone turnover.
Efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir Aaafenamide (E/C/F/TAF) in HIV-1/Hepatitis B coinfected adults. Gallant J, Brunetta J, Crofoot G et al. J Acquir Immune Defic Syndr. 2016 May 11 [Epub ahead of print]
Findings from a meta-analysis of published studies suggest chronic HBV may decrease the risk of pre-eclampsia.
The reviewers found three observational cohort studies and eight case-control studies, including 11,566 preeclampsia patients, conducted up to 1 January 2016 in Asian populations. A significant negative association between chronic HBV infection and pre-eclampsia was observed (odds ratio 0.77).
The reviewers suggest future prospective cohorts in different countries with larger sample sizes are warranted to ascertain the causality. Pathophysiological studies are required to explore the possible biological mechanisms involved, they added.
Chronic hepatitis B infection is associated with decreased risk of preeclampsia: a meta-analysis of observational studies. Huang QT, Chen JH, Zhong M et al. Cell Physiol Biochem. 2016 May 9;38(5):1860-1868 [Epub ahead of print]
HBV infection is possible following hemodialysis, especially among severely immunosuppressed patients.
Following an investigation of a report made in March 2013, US public health authorities, from the Epidemic Intelligence Service, have warned of this possibility, and recommended stringent infection control.
They found that the patient's only identified HBV risk factor was hemodialysis treatment, and that the facility had no other patients with known active HBV infection.
An investigation of one patient with evidence of a resolved HBV infection indicated HBV reverse seroconversion and reactivation had occurred in the setting of HIV infection and a failed kidney transplant.
HBV whole genome sequences analysis from the index and source patients indicated 99.9% genetic homology. Facility observations revealed multiple infection control breaches. Inadequate dilution of the source patient's sample during HBV testing might have led to a false-negative result, delaying initiation of hemodialysis in isolation.
Hepatitis B reverse seroconversion and transmission in a haemodialysis centre: a public health investigation and case report. Rhea S, Moorman A, Pace R et al. Am J Kidney Dis. 2016 May 7 [Epub ahead of print]
A paper has just been published in Nature by the chair of the Alcohol Health Alliance and colleagues making the case that improving public knowledge about alcohol harm will increase government appetite for regulation.
The paper, Alcohol: taking a population perspective, can be read in full > here.
NURSES TRAVEL BURSARY 2016
We are delighted to announce that AbbVie UK Ltd is offering 30 bursaries to support nurses attending the BASL Annual Meeting 2016. This will be open to all Nurses in the UK, both members and non-members of the BASL Nurse Forum.
The bursary application deadline is Friday 10th June 2016.
By Monday 27th June you will be advised of the status of your submission and the deadline for confirmation of acceptance is Monday 4th July.
Please email a copy of your application form to email@example.com AND post the original signed copy to: BASL Secretariat c/o Executive Business Support Ltd, City Wharf, Davidson Road, Lichfield, Staffordshire WS14 9DZ.
BASL must receive your application (both hardcopy and email) by the deadline of Friday 10th June. You can download further information below:
This travel bursary is funded by AbbVie Ltd, however, AbbVie Ltd have no involvement in the selection of the recipients of the bursary. Details regarding the application and review process for the scholarships can be found as part of these Guidance Notes.
BASL Nurse Forum Ward Membership is here, join today:
- £100 per annum for up to 5 members per ward
- Names of up to 5 ward members can be added at any point in the same membership year, up to the max of 5
- Ward member names can be updated annually
- Ward member benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September, and BASL member e-newsletters
- Payments can be made by invoice.
Sign up your Ward today by sending an email to firstname.lastname@example.org. A main point of contact for the Ward is required who will be contacted by the BASL Secretariat to obtain further details to set up the Ward Membership.
Although in HCV studies, SVRs above 90% have been achieved with direct-acting antiviral (DAA) combinations, outcomes in real-world patients are lower. In a review, authors from Spain and the UK have discussed the management of HCV treatment failure and the impact of resistance-associated variants (RAVs) on re-treatment strategies.
The authors say that failure to DAA combinations occurs more often in chronic HCV patients with baseline predictors of poor response, such as those with RAVs, genotypes 3 or 1a, advanced liver cirrhosis, elevated serum HCV-RNA and perhaps HIV coinfection. Impaired antiviral efficacy is more frequent when multiple factors are present.
On-treatment predictors of DAA failure are poor drug adherence and development of side effects. Extending the length of therapy, adding ribavirin and/or using DAA from other drug families may allow successful re-treatment of most prior DAA failures.
Prevention and management of treatment failure to new oral hepatitis C drugs. Benítez-Gutiérz L, Barreiro P, Labarga P et al. Expert Opin Pharmacother. 2016 May 5. [Epub ahead of print]
Findings from a new study suggest a significant relationship between skeletal muscle weakness and neurological impairment in cirrhotic patients.
This cross-sectional multi-centre study in Brazil included 54 cirrhotic outpatients with hepatic encephalopathy (HE) varying from subclinical to grade II, who were submitted to neuropsychometric tests, electroencephalogram, brain Single Photon Emission Computed Tomograph, anthropometric measurements, handgrip strength and dual energy X-ray absorptiometry exam.
Analysis of the area under the receiver operator characteristic curve revealed the values related to neurological manifestations (HE grades I and II). Reductions in adductor pollicis muscle thickness and hand grip strength were associated with higher HE grades, suggesting a big impact caused by the loss of muscle mass and function on HE severity.
Lower values of handgrip strength and adductor pollicis muscle thickness are associated with hepatic encephalopathy manifestations in cirrhotic patients. Augusti L, Franzoni LC, Santos LA et al. Metab Brain Dis. 2016 Apr 30. [Epub ahead of print]
Dr Gideon Hirschfield and Dr James Ferguson, on behalf of the Birmingham Liver Unit, are organising a Liver Course in Birmingham on 26-27 May 2016, to be hosted at the Medical School, University of Birmingham, for colleagues from across all specialties who work locally, regionally and nationally.
The full programme covers practical and pressing issues in the management of advanced liver disease with speakers from around the country who are experts in their field. Using an interactive approach, for the fourth year running, we are sure this course will prove to be very popular and of interest to trainees, consultants, nurses and allied health professionals.
To view the prgramme and to find out how to register click here.
The International Co-infection Workshop in Berlin is a two day abstract-driven meeting consisting of invited lectures, oral abstract presentations and poster viewing sessions.
In order to ascertain an interactive workshop setting, time is allocated to Q&A sessions and discussions. The target audience consists of clinicians involved in daily care for co-infected patients; researchers, PhD students and all those interested in the best treatment possibilities of co-infected patients. The workshop is a clinically focused meeting where world experts are present to share their experience and discuss their data. The cross-disciplinary sharing of information between hepatologists and infectious disease experts creates a unique opportunity to further improve the daily management of HIV and Hepatitis co-infected patients.
For more information and to find out how to register click here.
BASL members will receive a 25% discount on the registration fee - enter the following code when you register - 12CO-BA.
The 5th APASL Single Topic Conference on Hepatitis C will be held at Kaohsiung Exhibition Center in Kaohsiung, Taiwan from June 10-12, 2016.
Early Bird Registration & Abstract Submission is Now Open. The deadline for abstract submission has been extended to 30th April 2016.
APASL STC in HCV Kaohsiung in Taiwan 2016 is organized by The Asian Pacific Association for the Study of the Liver (APASL) and The Taiwan Association for the Study of the Liver (TASL). The conference will focus on viral hepatitis, specifically in the field of the knowledge on Hepatitis C virus. The overall theme will include to present vigorous researches and clinical experiments in hepatology as well as all aspects aiming for a better understanding of the Hepatitis C virus infection in practical preventions to a breakthrough in advanced treatments.
Please click here to visit the website for more information.
Booking is now open for the BVHG meeting at The Royal College of Surgeons, Edinburgh.
The recent BVHG meetings have been very successful, looking at a range of issues in viral hepatitis care, research, therapy and immunosuppression. We are continuing our themes by having this meeting examining the developments in Hepatitis B and E. Clinicians with significant experience in these fields will update us on present knowledge and practice and we hope that you can join us.
To view the programme and to book click here or on the link below.
BHIVA in collaboration with BVHG are delighted to announce the second Hepatology Highlights Meeting of 2016. This meeting is free to attend and will take place on the evening of Wednesday 15 June 2016 at the Royal Society of Medicine from 17:45 - 20:00 p.m. It will cover the latest updates in the treatment of HIV/Hepatitis Co-infection.
Programme - a Provisional Programme is available to view; please click here.
Registration - online Registration is now open and you can register click here.
Please note that places are limited and will be allocated, in principle, on a first-come, first-served basis.
2 CPD accreditation points have been applied for.
The meeting is endorsed by the BVHG.
The Institute of Liver Studies at the King's College Hospital, London will be hosting a two day meeting focused on current liver medicine and scientfic knowledge with a strong view on developments likely in the near future. The meeting will acknowledge the 50th year of the 'King's Liver Unit’.
The scientfic programme will be led by King's College Hospital Liver Team to bring together an international faculty of alumni, research collaborators and associates from centres of excellence and leading the field of liver research and medicine.
The programme will look at the specialty's achievements to date and celebrate the advancement in Transplantation, Liver Molecular Genetics, Liver Immunopathology and Hepatocyte Biology through to reviewing established and innovative therapies for liver disease, including new surgical techniques. The programme will encompass adult and paediatric specialities.
Visit www.kingslivercourse.org and register your interest.
The BSG Annual Meeting 2016 will once again return to Liverpool from Monday 20 to Thursday 23 June at the ACC, Liverpool.
The four day annual meeting will begin on Monday with the Gastroenterology Masterclass, which will host world renowned speakers from the UK, providing cutting-edge updates, state-of-the-art lectures and interactive sessions on managing endoscopic complications.
The main scientific programme (Tuesday - Thursday) will include basic and clinical science symposia, state-of-the-art lectures, clinical updates, moderated poster rounds and industry exhibition. New for 2016 is a whole day of live endoscopy which will focus on getting the basics right. The topic for the Thursday Scientific Translational Masterclass is the Gut Neuroendocrine System.
Further details: http://www.bsg2016.org.uk/
BASL School of Hepatology will be held at Nottingham University Park Campus over 2nd and 3rd July 2016 ENROL VIA THE 'BOOK NOW' BUTTON AT THE BOTTOM OF THE PROGRAMME
The event, including overnight accommodation, is free to attend for all medical qualified BASL members in training, restricted to 40 delegates
Friday 1st July
Evening Arrival at venue at delegates’ own leisure
Saturday 2nd July
09.30-09.40 Introduction and Welcome
Dr Martin James (Nottingham University Hospital)
09.40-10.10 Burden of cirrhosis, incidence trends and mortality - Learning Objectives: Understanding risk factors and the increasing burden of liver disease in the UK & predicting mortality
10.10-10.40 Detection of cirrhosis; are LFTs any good?
Dr Dave Harman
Learning Objectives: Challenging conventional strategies for detecting liver disease. Is finding asymptomatic, pre-clinical liver disease possible or worthwhile?
10.40-11.00 Panel interaction & questions
Conversations with investigators:
11.15-11.45 Treating alcoholic hepatitis - Learning Objectives: Where does the STOPAH data lead us in clinical practice and exploring novel therapies for acute alcoholic hepatitis?
11.45-12.15 Diagnosing & treating NASH - Learning Objectives: Risk factors, clinical scores and histological features. When should we start drug therapy?
12.15-12.45 Panel interaction & questions
13.30-14.00 Stratifying and monitoring HCV - Prof Will Irving
Learning Objectives: Lessons from HCV UK and laboratory insights into monitoring and treating HCV infection
14.00-14.30 Treating HCV in 2016 & beyond? - Prof Graham Foster
Learning objectives: The present and future treatment strategies for HCV infection in the UK. Can we afford not to treat?
14.30-15.00 Panel interaction & questions
Consequences of cirrhosis-1
15.15-15.45 Surveillance for HCC - Learning Objectives: Examine the evidence and challenges of HCC surveillance
15.45-16.15 Radiological diagnosis HCC - Learning Objectives: Imaging modalities and algorithms for HCC diagnosis
16.15-16.30 Panel interaction & questions
19.00 Dinner in the Council Dining Room - 7pm Drinks Reception - 7.30pm Meal
Sunday 3rd July
Evidence based practice; consequences of cirrhosis -2
09.15-09.45 Treatment options in HCC - Learning Objectives: Understand curative and non-curative options for HCC management; can science help?
09.45-10.15 Symptomatic & palliative care in liver failure & HCC - Dr Ben Hudson -Learning objectives: Predicting and preparing patients for liver failure and death. Who, where and how?
10.15-10.30 Panel interaction & questions
Evidence based practice; consequences of cirrhosis -3
11.00-11.50 Surveillance & treatment for varices - Learning Objectives: Review of updated 2015 varices management guidelines.
12.40-13.00 Treatment strategies for cirrhotic ascites - Dr Emilie Wilkes
Learning objectives: Novel approaches to patient and nurse-led management of cirrhotic ascites
13.00 Close of meeting
All further enquires to email@example.com Tel: 01543 442154
Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.
Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.
To find out how to apply click here.
The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account